9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Comment on “The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region” and reflections from the Italian Association of Oncology Nurses

      letter
      , RN, MSN, PhD a , , RN, MSN, PhD(s) b , , RN, MSN, PhD a , , RN c , , RN, MSN, PhD d ,
      European Journal of Cancer
      Elsevier Ltd.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the editor: We thank Trapani et al. [1] for their contribution aimed at sharing the experience of the reorganization of cancer care to respond to COVID-19 in the Lombardy Region (Italy). Trapani et al. [1] described the Italian cancer mortality and an interim analysis of nine cancer patients with COVID-19, mainly managed using home-based management. We agree with the authors in identifying the continuum of care as the key to success in COVID-19 and cancer management, as well as the strong need of keeping the connection between health needs and cancer management. Forasmuch, in accordance with what highlighted by Trapani et al. [1], the Italian Association of Oncology Nurses (AIIAO) is mapping the situation of the cancer patients self-isolated at home in the context of the COVID-19. On the 9th March 2020, the Italian authority locked down the country to contain the spread of COVID-19. Specific recommendations were provided to people living with cancer, who were encouraged to stay at home in self-isolation, especially elderly and immunocompromised patients, since they were considered at increased risk of COVID-19 infection and severe events [2]. Moreover, non-urgent visits were postponed, and several specialist cancer wards were converted into isolation units for patients with COVID-19 infection or closed because of staff shortage [3]. Furthermore, cancer patients are in urgent need of blood monitoring, chemotherapy, scans, transplants, and surgery, which, if delayed indefinitely, could mean loss of the window to treat. In this context, we started an online survey to describe the situation of the cancer patients self-isolated at home in the context of the COVID-19. Thus far, we have performed an interim analysis for data collected between 29th March and 3rd May 2020. Accordingly, 195 patients completed the survey. They were mainly female (n = 148, 75.9%), with a mean age of 50.3 (SD = 11.2, range = 25-78) years and a high level of education (university or postgraduate = 66, 34%). The majority of patients had haematological malignancies (n = 100, 51.3%), followed by patients with breast cancer (n = 51, 26.2%), and other solid tumours (n = 44, 22.6%). The majority were from the north of Italy (38.9%), 34.7% from the south, and 26.4% from central regions. Table 1 shows patients’ beliefs, behaviour, and access to care. Table 1 Participants’ beliefs, behaviour, and access to care (n = 195). Table 1 n % Leaving the house  Never 41 21.1  Rarely 115 59.3  Sometimes (2-3 times per week) 23 11.9  Every day 15 7.7 Reason for leaving the housea  Health 96 49.7  Job 16 8.3  Supermarket 97 50.3  Walking 25 13.0  Never going out 28 14.5 COVID-19 risk infection  I believe I am at higher risk 105 53.8  I believe I am not at higher risk 90 46.2 I believe I will suffer from severe consequences in case of infection due to my cancer  Very much/Completely 99 50.8  Quite a bit 46 23.6  A little/Not at all 50 25.6 Behaviours to lower infection riska  Hand washing 180 95.2  Social distance 154 81.5  Face mask without valve 136 72.0  Face mask with valve 46 24.3  Gloves 105 55.6  Disinfecting surfaces/cloths/groceries 56 29.6 Changes in relating with family membersa  Nothing changed 107 56.0  No kisses and hugs 61 31.9  Social distance 23 12.0  Separate rooms 13 6.8  Other 13 6.8 Using remedies to prevent COVID-19 infection  Yes 57 29.2  No 138 70.8 Health status under control  Yes 137 71.0  No 56 29.0 Fear of going to the hospital  Very much/Completely 72 37.3  Quite a bit 40 20.7  A little 65 33.7  Not at all 16 8.3 Frequency of going to the hospital  Not going at all 73 37.8  Diminished frequency 46 23.8  Same frequency as usual 68 35.2  Other 5 2.6 a multi response variable. Overall, an important number of patients reported that their cancer disease was not under control (29%). This is especially alarming given that one patient out of four experienced difficult access to safe cancer care (24%), especially regarding follow-up visits, which were often postponed. Cancer patients not only were considered at higher risk for COVID-19 infection, but they also paid the price for an emergent imperative to reduce cancer care activity associated with several factors [4]. These included the need to respect imperative social distancing, the lack of beds in intensive care units, the increased workload [5], the reduction of the oncology workforce caused by the re-allocation of healthcare providers into COVID-19 units or quarantine at home, and shortages of personal protective equipment [6]. Another important factor to consider is that cancer patients were afraid to go to the hospital even when they needed and sometimes decided to cancel their appointments. Stay-at-home campaigns may have reinforced people’s awareness about the importance of self-isolation as an effective preventive measure for reducing virus spread and the risk of infection. However, they may also have increased the perception of hospitals as places where people get infected. This could have added further uncertainty to patients whose illness anxiety has already been negatively influencing their mental well-being [7]. Moreover, participants reported the fear that their cancer disease would be regarded as of secondary importance. In light of this consideration, health professionals should help patients in prioritizing their own health needs [8]. Participants reported to take several measures to reduce their infection risk, including hand washing, use of facemasks and gloves. Since cancer patients usually feel more vulnerable than the general population and are more used to hypervigilance and protective measures, it is not surprising that they adopted preventive behaviours promptly. However, only 54% believed to be at higher risk for COVID-19 infection and 51% for complications. The scarcity of information about who was at higher risk and the reassuring attitudes of many clinicians may have contributed to this perception. Besides, participants had clear in mind the importance of maintaining a positive attitude in light of difficult circumstances. In fact, cancer patients could be considered experts in adapting to the new normal. Among spontaneous preventive behaviours, about one-third of participants reported taking supplements as remedies to reduce the likelihood of being infected. These included vitamins C and D, which were not specifically recommended by health professionals due to the lack of evidence from clinical trials still ongoing [9]. On the one hand, this is not surprising as patients feel that they should be doing something on their own and are thereby continuously searching for supplements able to protect their body’s cells and tissues from oxidative damage and dysfunction while supporting healthy immune function. On the other hand, self-care strategies such as a well-balanced diet, regular exercise, and good relationships seem underestimated for their potential to support the immune response, without interfering with the actual cancer treatment. In conclusion, we would like to stress again what expressed by Trapani et al. [1]: “Understanding and implementing the scopes and goals of the global responses and enforcing community flexibility, and not merely advocating for a patient-centred approach. The resilience, capacities, skills and resources of the context must be recognized, and these must be built on to deliver protection and solutions while supporting the community's own goal. The ultimate goal now is to end COVID-19 as one global community”. To success in COVID-19 and cancer, the understanding of the unanswered health needs of cancer patients is pivotal, and it is needed a multi-professional call to action to build a sound strategy in every context. Conflicts of Interest and Source of Funding The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found

          Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

          There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic

            There is an urgent need to share expertise and offer emergency guidance for breast radiation therapy (RT) during the COVID-19 (Coronavirus) pandemic. As per the World Health Organisation (WHO) statement, our aim and obligation should be “to stop, contain, control, delay and reduce the impact of this virus at every opportunity”. In our roles as healthcare professionals and/or breast cancer experts this translates to minimising exposure of our patients to COVID-19 without compromising oncological outcome. It is imperative that hospital visits are kept to the absolute minimum and that the complexity of RT planning/treatment is reduced where possible to ease pressure on our workforce. Given that breast RT accounts for 30 per cent of delivered RT fractions, the following recommendations require particularly urgent consideration. By adopting these recommendations where RT is minimised and targeted to those with the highest risk of relevant breast recurrence, we aim to protect our patients and health care professionals from potential exposure to COVID-19 as well as reducing the workload for health care providers and/or infrastructure at the moments that resources face strain due to the pandemic. A general guiding principle in this unusual setting is that: (i) where clinical equipoise has been sufficient to support the conduct of randomised trials testing a less resource-intensive approach, and (ii) results available to date have not provided evidence that such a test arm is clearly inferior, then (iii) the approach involving fewest patient visits and duration should be encouraged in the context of a pandemic like COVID-19 even when level 1–2 evidence has not formally been delivered. We suggest that the following guidelines are considered and the risks and benefits are discussed with patients to facilitate shared decision-making. Centres may need/choose to delay RT depending on local circumstances with reference to expert consensus following previous natural disasters [1] and also amend current systemic therapy pathways, but this is outside the remit of these guidelines. 1. Omit RT for patients 65 years and over (or younger with relevant co-morbidities) with invasive breast cancer that are up to 30mm with clear margins, grade 1–2, oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative and node negative who are planned for treatment with endocrine therapy [2]. Trials investigating safe omission of RT can be considered if they do not impact on patients visits and resources are available. Centres may also consider omitting RT for ductal carcinoma in-situ (DCIS) depending on individual risk and benefit. 2. Deliver RT in 5 fractions only for all patients requiring RT with node negative tumours that do not require a boost. Options include 28–30Gy in once weekly fractions over 5 weeks or 26Gy in 5 daily fractions over 1 week as per the FAST and FAST Forward trials respectively [[3], [4], [5]]. N.B. 5-year local relapse data are not yet available for FAST Forward but imminent publication is anticipated. In the meantime, 26Gy in 5 fractions has already been demonstrated to be equivalent with 40 Gy in 15 fractions with respect to 3-year normal tissue outcome. Furthermore, local control is likely to be within acceptable limits given the low local relapse rates in this patient group generally [6]. The FAST Forward protocol and RT planning pack are available at: https://www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/clinical-trials/fast_forward_page/ Partial breast RT using 28.5-6Gy in 5 fractions over 1–2 weeks [7,8] can also be considered for selected patients if resources are available for increased complexity and/or to avoid deep inspiration breath hold (DIBH) for left-sided tumours in the upper half of the breast (if DIBH impacts on treatment time). N.B. IMPORT Low [6] has the same fractionation schedule in the control group as FAST Forward so 26Gy in 5 fractions over 1 week could also be proposed in the partial breast irradiation setting. 3. Boost RT should be omitted to reduce fractions and/or complexity in the vast majority of patients unless they 40 years old and under, or over 40 years with significant risk factors for local relapse [9]. Boost RT has no proven survival advantage so risks and benefits during the COVID-19 pandemic need to be re-evaluated. An example of a significant risk factor is the presence of involved resection margins where further surgery is not possible. Any boost should be either simultaneous and integrated to minimise fractions if resource permits or hypofractionated sequential, e.g. 12Gy in 4 fraction over 4 days. 4. Nodal RT can be omitted in post-menopausal women requiring whole breast RT following sentinel lymph node biopsy and primary surgery for T1, ER positive, HER2 negative G1-2 tumours with 1–2 macrometastases [10]. This approach gives this group of patients the option of 5 fractions of RT, and may reduce complexity of planning/treatment. 5. Moderate hypofractionation should be used for all breast/chest wall and nodal RT, e.g. 40Gy in 15 fractions over 3 weeks [[11], [12], [13], [14]]. The use of moderate hypofractionation is already the standard of care in many countries and in the altered risk-benefit context of a pandemic should be strongly considered in patients with breast reconstruction. However, many centres will halt immediate reconstruction during the pandemic as this is not essential cancer surgery.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective

              At the end of 2019, a novel severe acute respiratory syndrome (SARS) coronavirus (CoV), named SARS-CoV-2 or 2019-nCoV, has been identified as the microbial agent causing viral pneumonia in several patients epidemiologically linked to a seafood market in Wuhan (Hubei province, China).1 2 Since then, the spread of coronavirus disease 2019 (COVID-19) has progressively involved countries outside China leading the World Health Organization (WHO) to make the assessment that COVID-19 can be characterised as a pandemic.3 Outside China, Italy has the largest COVID-19 outbreak with 37 860 confirmed cases and 4032 deaths according to the data of ‘Istituto Superiore di Sanità’ on 20 March 2020.4 In order to limit viral spread, the Italian Government has implemented extraordinary measures which culminated on 9 March in a lockdown inhibiting—unless strictly required—people’s movements and social activities throughout the national territory.5 The Italian National Health System is currently under pressure and remarkable efforts are spent to provide an efficacious reaction to the emergency. As Italy is experiencing a chronic shortage of healthcare workers, the government announced a plan to recruit 20 000 new doctors, nurses and hospital employees, to meet public demand, on 9 March.6 Retired doctors may be called on as well as residents who have completed their medical degree and are in the final year of specialist training. Meanwhile, doctors who have come into contact with patients affected by COVID-19 are encouraged to work unless they show symptoms of the infection or have a positive test for SARS-CoV-2. However, allowing untested healthcare personnel to take care of patients may be a double-edged sword due to the fact that undocumented infections may be the primary source of documented cases.7 Moreover, shortages of personal protective equipment (PPE) appear to be widespread across the health service and include general practitioner practices as well as hospitals. Specific algorithms and protocols within the Emergency Medical System are being implemented, including the attempt to increase intensive care unit (ICU) capacity.8 9 For this purpose, especially in most affected areas, medical specialists including oncologists have been recruited to provide their assistance in managing patients suffering from COVID-19 requiring hospitalisation in ICUs, departments of infectious or respiratory diseases, or general internal medicine. Older adults and patients with pre-existing comorbidities (commonly diabetes and cardiovascular disease) are facing the most severe and critical consequences of the SARS-CoV-2 outbreak.10 11 Age is also a risk factor for cancer development,12 and patients with cancer are more susceptible to infections as compared to healthy subjects due to systemic immunosuppression secondary to both the malignancy and anticancer treatments.13 Hence, the current emergency is of particular concern to medical oncologists and their patients. In the first article focusing on oncological cases affected by COVID-19, Liang and colleagues concluded that the risk of SARS-CoV-2 infection was higher in patients with cancer who deteriorated more rapidly in the clinic and had a higher risk of severe events including the necessity for admission to the ICU or death.14 Older age remained the only risk factor associated with severe events from SARS-CoV-2 infection among patients with cancer. The authors suggested three measures for reducing the burden of COVID-19 in oncology in endemic areas: to postpone treatments or elective surgery for stable cancer in endemic areas, to provide stronger personal protection provisions to patients and, finally, to offer more intensive surveillance or treatment for patients infected with SARS-CoV-2.14 In this situation of emergency for healthcare systems, the inability to receive needed medical services is an additional concern.15 The issue on how to organise cancer care during the COVID-19 pandemic is crucial.16 In order to provide some guidance on cancer care during the Italian SARS-CoV-2 outbreak, the Italian Association of Medical Oncology (AIOM) in partnership with the boards of Academic Oncologists (COMU) and of Oncology Unit Directors (CIPOMO) has recently proposed some critical recommendations for patients currently receiving active treatments, those in follow-up (ie, out of active treatment), as well as for the admission of patients and their caregivers to the hospital.17 For patients currently receiving active treatments, oncologists are invited to consider, on a case-by-case basis, the possibility of a delay in treatment administration. The decision of confirming the scheduled administration or delaying treatment should be based on the biological features of the tumour, the clinical condition of the patient with his/her symptoms, treatment characteristics (ie, expected benefit and adverse events including myelosuppression), disease response to current anticancer therapy, and the potential risks for an infection with SARS-CoV-2. An alert about the use of checkpoint inhibitors is raised by the identification of the cytokine storm-induced hyperinflammation as a pathogenetic mechanism for COVID-19-associated pneumonia of severe clinical scenarios.18 However, it should be recognised that an evidence-based estimation of the impact of treatment delay or interruption on the risk/benefit balance for each individual patient is currently lacking. For patients who are currently in follow-up (ie, out of active treatment), oncologists should consider to avoid disease-free patients coming to the hospital for routine follow-up visits. A phone call/online exchange of clinical documentation can be useful to reassure patients, and refrain from consultation at the hospital except for the case of an emergence of new symptoms or new clinical or radiological signs of disease progression. Regarding admission to the hospital, outpatients scheduled for treatment should come alone and avoid the assistance by a caregiver except for documented need of continuous assistance. Triage of patients with fever and/or respiratory symptoms is essential to prevent exposure to other patients and healthcare providers.17 As young oncologists working in different regions, we are all implementing these recommendations (table 1). The overall goal of all these recommendations is the attempt to maintain cancer care in the frame of an environment as safe as possible for both patients and healthcare providers. Notwithstanding some adaptations based on the specific directives of single institutions, the high level of homogeneity on how these measures are being implemented across centres is reassuring for the Italian oncology community and patients with cancer. Table 1 Practical suggestions on how to implement cancer care during the COVID-19 outbreak Patients currently receiving or who need to start active treatments Patients in follow-up (currently out of active treatment) Admission of patients and caregivers to the hospital Other occasions of regular face-to-face interaction Case-by-case evaluation of the risk/benefit ratio of delaying anticancer treatment* Start or continue all adjuvant/neoadjuvant treatments (or any other potentially curative therapy), as well as first-line therapies for metastatic disease Delay all treatments beyond first-line therapy with modest efficacy expected (unless there are urgent clinical reasons), maintenance therapies and treatments in patients with low disease burden and slow progression Delay imaging procedures to monitor treatment response (unless there are urgent clinical reasons) Shipment of oral drugs or dispensing of multiple treatment cycles, if feasible, based on supply availability and patients’ characteristics Replace scheduled visits not associated with therapy prescription/administration with email or phone contact (unless there are urgent clinical reasons) Phone call by the clinician in order to perform a quick triage of the clinical condition, and allow the examination of lab and/or imaging exams* To allow access to the hospital for regular consultations in the following cases: Suspected disease progression Need for a new prescription of active treatments (eg, adjuvant endocrine therapy for breast cancer) Strong desire of the patients to perform a regular physical examination No caregiver allowed for all outpatients scheduled for treatment except in the case of documented need of a continuous assistance* Maximum one caregiver allowed (after triage) for every inpatient Quick triage of clinical condition before entering the hospital; no access allowed in the case of fever and/or respiratory symptoms (COVID-19 path to be followed in these cases)* Surgical masks and handwashing with hydrohalcoholic gel provided to all patients at the entrance Limiting points of entry to the hospital with separated paths for accessing the hospital for patients and hospital personnel To avoid all face-to-face meetings (including multidisciplinary tumour boards that can be virtually organised), congresses, seminars and lectures intended for residents and PhD fellows, visits from pharmaceutical companies Cancellation of any group activity (eg, group therapy, recreational activities, etc) *Corresponding to the recommendations published by the Italian Association of Medical Oncology (AIOM) in partnership with the boards of Academic Oncologists (COMU) and of Oncology Unit Directors (CIPOMO). COVID-19, coronavirus disease 2019. However, some opinions diverging from the described strategies have been voiced: for example, some colleagues have raised concerns regarding the delay of treatment for advanced disease or cancer screenings of healthy individuals.19 We believe that in the context of the current emergency situation and considering the severely increased strain on our National Health System, the delay of the mentioned procedures is reasonable and realistically unavoidable. We are not advocating distraction, but we are clearly pointing to the necessity to save the life of thousands of people. As we are facing a rapidly evolving and unprecedented emergency, we are all forced to constantly reconsider and critically re-evaluate our opinions. Special additional challenges for oncologists include the differential diagnosis between SARS-CoV-2 infection and clinical and radiological findings related to drug-mediated toxicity (eg, immunotherapy), other infectious agents or cancer progression requiring specialised expertise of medical oncologists. Moreover, the management of patients with cancer also affected by COVID-19 represents a further need which should guarantee both active and potentially life-saving anticancer treatments as well as palliative and end-of life care. In addition to the above recommendations, face-to-face interactions should be consistently restricted in this emergency period (table 1). As young oncologists living in the era of technology and social media, this difficult moment may serve as the basis to implement telemedicine whenever possible and feasible.20 Massive efforts should be put into monitoring of patients at home with regular contacts by telephone, electronic text transmission, email or smartphone apps. In these particular situations, such strategies could also help to alleviate patient isolation and loneliness by psychological interventions. Although ‘telehealth’ cannot be the only future strategy of medicine considering the relevance of patient-doctor interactions which are of special relevance in the field of oncology, the current crisis of the healthcare system necessitates the use of electronic communication as a valid tool to further optimise cancer care (eg, management of follow-up visits, oral therapies, etc) in such difficult circumstances. As a final important note, the COVID-19 crisis is also hindering cancer research. Special considerations related to this regard should be highlighted and faced also considering the particular heterogeneity of available resources in the different units across the country (Box 1). The Food and Drug Administration, the European Medicines Agency (EMA) and the Italian Medicines Agency have issued special guidance for the conduction of clinical trials during the COVID-19 emergency.21–23 Box 1 Main challenges for cancer research during the COVID-19 outbreak Minimise or delay the opening of new clinical trials. Limit or hold patients’ accrual in ongoing trials requiring extra procedures as compared with clinical practice.* Need to refer on-study patients to other active centres in the case of difficulties in continuing the planned treatment due to COVID-19-related reorganisation. Smart working for data managers and study coordinators. Possible treatment delays or problems in drug supply for logistic reasons around COVID-19. Need for telephone contact report to replace in-person follow-up visits to be included within the patient’s clinical notes. Cancel or delay onsite monitoring visits. Preserve both scientific validity of results and safety of patients and trial staff by implementing decision sharing and strict contacts with the sponsors. *This decision should be based on multiple aspects: the structure and organisation of the oncology centre and the consequent ability to ensure extra procedures (ie, independent cancer centre or oncology department integrated within a general hospital), the type of study and the burden of extra procedures required, ethical considerations related to trial design (ie, presence of a placebo arm), the expected benefit that the patient could derive from the participation into the trial. Despite all these challenges associated with the COVID-19 epidemic in Italy, we as professionals who take care of a frequently frail patient population in a delicate phase of their life should make all the possible efforts to mitigate the risk of suboptimal management of patients with cancer including those with concurrent COVID-19 infection. Considering the added extra burden of the epidemic for our patients and for all healthcare providers, also including the hard consequences of social distancing and isolation as well as a restriction in family interactions, the provision of encouragement and emotional help is essential. Our generation is facing such a tremendous crisis for the first time, but our commitment and extra energy as young oncologists are crucial to fight and succeed in this difficult situation which calls for the continuation of the provision of compassionate and safe care for our patients with cancer. Our young oncologists’ perspective (YOP) on protection against COVID-19 can be summarised by making the same acronym Y-O-P. Protect: Yourself, and your family: at work, with constant focus and attention on PPE, and in personal life, by following all the official instructions and respecting lifestyle restrictions. Oncological care of our patients, delaying what can be delayed, but trying as much as possible to minimise the impact of the emergency on the usual standard of care. Patients’ themselves from being infected, making any possible effort to minimise the risks and giving continuous direction and appropriate official information.
                Bookmark

                Author and article information

                Contributors
                Journal
                Eur J Cancer
                Eur. J. Cancer
                European Journal of Cancer
                Elsevier Ltd.
                0959-8049
                1879-0852
                4 June 2020
                4 June 2020
                Affiliations
                [a ]Department of Medicine and Psychology, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy
                [b ]Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1,00133, Rome, Italy
                [c ]Associazione Italiana degli Infermieri di Area Oncologica (AIIAO), European Institute of Oncology; via Ripamonti 435, Milan, Italy
                [d ]Health Professions Research and Development Unit, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
                Author notes
                [] Corresponding author. Head of Health Professions Research and Development Unit, IRCCS Policlinico San Donato, Via Agadir, 20-24 20097 San Donato Milanese (Mi). Tel.: +39 0252774940; fax: +39 0252774969. rosario.caruso@ 123456grupposandonato.it
                Article
                S0959-8049(20)30299-9
                10.1016/j.ejca.2020.05.022
                7269936
                b93108fc-036c-4475-8f3f-a6a61bf5474a
                © 2020 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 14 May 2020
                : 20 May 2020
                Categories
                Article

                Oncology & Radiotherapy
                Oncology & Radiotherapy

                Comments

                Comment on this article